1Fried MW, Schiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for patients with chronic hepatitis C virus infection. N Engl J Med, 2002, 347: 975-982.
2Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet,2001, 358: 958-965.
3Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology, 2003, 124: 1711-1719.
4DE Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis c virus infection:role of membrane oxidative damage. Hepatology,2000, 31: 997-1004.
5Shiffman ML,Hofmann CM, Luketic VA, et al. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alfa-2b for treatment of chronic hepatitis C. J Hepatology,1998, 28:382-389.
6Pockros PJ, Duchini A, McMillar R, et al. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection.Am J Gastroenterol, 2002, 97: 2040-2045.
7Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology, 1997, 26: 206-210.
